A comprehensive genomic study reveals striking disparities in cancer risk among pediatric patients carrying different pathogenic germline variants. The research, published in Nature Medicine, identified that children with TP53 variants face the highest subsequent cancer risk at 32%, followed by RB1 variants at 24%, BRCA variants at 16%, and mismatch repair variants at 12%. Across all variant types, 18% of pediatric patients with pathogenic germline mutations developed subsequent cancers.
These data-driven findings highlight the importance of gene-specific risk assessment in pediatric populations. The significant variation in cancer development rates across different cancer-predisposition genes suggests that genetic testing results should directly inform the intensity and frequency of clinical surveillance protocols. Understanding which variants confer the greatest risk enables clinicians to allocate resources efficiently and prioritize intensive monitoring for the highest-risk patients.
Read the full article on GMJ Newsroom.
Was this article helpful?
